API & Fine Pharmaceutical Manufacturer in India
Sucroferric Oxyhydroxide
Product Name

Sucroferric Oxyhydroxide

Molecular Formula C12H29Fe5Na2O23
Molecular Weight 866.5 g/mol
CAS No 1007207-67-2
CID Code 91663255
Shelf Life 3 years - 20°C powder
Pharmaceutical Grade Non-Pharmacopeial
USP of Products
  • Effective phosphate binder for chronic kidney disease patients receiving haemodialysis
  • Used in the treatment of iron-deficiency anaemia, including patients with chronic kidney disease
  • Gastrointestinal side effects are similar to those of current phosphate binders
If you are interested on Sucroferric Oxyhydroxide, then

Description of Sucroferric Oxyhydroxide

Sucroferric Oxyhydroxide (SO) is a non-calcium, iron-based, chewable phosphate binder indicated for the control of serum phosphorus levels in patients with end-stage renal disease (ESRD) receiving dialysis. There is minimal systemic iron absorption from sucroferric oxyhydroxide, and therefore the drug is associated with a low risk of iron accumulation. 

Application of Sucroferric Oxyhydroxide

  • Phosphate Binder: Sucroferric oxyhydroxide acts as a phosphate binder, reducing the absorption of phosphate from food in the gastrointestinal tract, which is essential for CKD patients.
  • Chronic Kidney Disease Management: It is specifically formulated for the management of serum phosphorus levels in adult patients with CKD on hemodialysis or peritoneal dialysis.
  • Lower Pill Burden: Compared to other phosphate binders, sucroferric oxyhydroxide often requires a lower pill burden, meaning fewer doses are needed, which can improve patient compliance and quality of life.
  • Non-Calcium-Based Binder: As a non-calcium-based phosphate binder, it offers an alternative for patients who may need to avoid extra calcium intake.
  • Iron Reutilization: The iron in sucroferric oxyhydroxide can be partially absorbed and contribute to iron reutilization, potentially benefiting patients with CKD who often suffer from anemia.
  • Nutraceutical Potential: There’s potential exploration into its use as a nutraceutical component for managing dietary phosphate among populations with elevated levels, not just limited to CKD patients.
  • Minimal Systemic Absorption: It is designed for minimal systemic absorption, which reduces the risk of systemic iron overload – a concern with some iron-based therapies.
  • Synergistic Use: Sucroferric oxyhydroxide can be used alongside other treatments for CKD, such as vitamin D analogs and calcium supplements, as part of a broader management strategy.
  • Reduced Pill Size: It’s formulated in smaller pills compared to some other binders, which can be beneficial for patients who have difficulty swallowing.
  • Safety Profile: Its unique chemical structure contributes to a safety profile that is favorable for long-term use in managing chronic conditions.
Related Products
L-ornithine L-aspartate (C9H19N3O6)
CAS No: 3230-94-2
L Ornithine L Aspartate
Dimethyl Fumarate (C6H8O4)
CAS No: 624-49-7 HSN Code: 29171990
Dimethyl Fumarate
Ascorbyl Palmitate (C22H38O7)
CAS No: 137-66-6 HSN Code: 29362700
Ascorbyl Palmitate
Ulipristal Acetate (C30H37NO4)
CAS No: 126784-99-4
Ulipristal Acetate
Calcium Butyrate food grade (C8H14O4Ca)
CAS No: 5743-36-2 HSN Code: 29156010
Calcium Butyrate Food Grade
Request for Product Enquiry

    Request Sample